September 16, 2026, (Inside AI) — ByteDance has closed a $290 million funding round for its artificial intelligence drug discovery unit, Anew Labs, following the division's spin-off from the Chinese technology giant. Two people with knowledge of the transaction confirmed the deal on Wednesday, placing the Shanghai-based company at a post-money valuation of $1.5 billion.
The financing marks Anew Labs' first external capital raise and represents a significant bet by major Asian investors on the intersection of generative models and pharmaceutical research. The round was led by HSG, formerly Sequoia China, IDG Capital, and Hillhouse Investment, with 5Y Capital serving as a co-lead investor.
Additional participants include Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group, and the state-backed Shanghai Future Industries Fund. ByteDance and the investors did not immediately respond to requests for comment. The sources spoke on condition of anonymity because the information is not public.
The spin-off allows Anew Labs to operate with a management structure distinct from ByteDance's core social media and advertising businesses. ByteDance will retain a 56% ownership stake following the fundraising, according to one source, preserving majority control while providing the unit with independent capital.
Read: ByteDance's First-Half Net Profit Falls to $20 Billion Amid Higher AI Spending
Why ByteDance Split Its AI Drug Unit
ByteDance executives determined that AI drug discovery follows a different industry logic and management approach than the group's core operations. The separation enables Anew Labs to pursue long-term research timelines that do not align with the quarterly pressures of a consumer internet conglomerate.
This strategic move mirrors a broader trend among technology firms seeking to unlock value from specialized AI research. By spinning off the unit, ByteDance can attract healthcare-focused investors who might otherwise avoid exposure to social media volatility. The structure also shields the parent company from the substantial capital requirements and regulatory scrutiny inherent in pharmaceutical development.
The involvement of the Shanghai Future Industries Fund signals local government support for AI-driven biotechnology. This backing aligns with China's national strategy to advance domestic innovation in both artificial intelligence and life sciences.
The valuation of $1.5 billion places Anew Labs among the more valuable private AI drug discovery firms globally. For context, similar companies in the sector have attracted significant funding as investors bet on AI's potential to reduce the time and cost of bringing new drugs to market. Traditional drug development often takes over a decade and costs billions of dollars, a process that AI models aim to accelerate by predicting molecular interactions and identifying promising compounds.
The list of investors reflects a mix of established venture capital and strategic capital. HSG, IDG Capital, and Hillhouse are among the most active technology investors in Asia. Their participation suggests confidence in Anew Labs' technical capabilities and the commercial viability of its platform.
ByteDance's decision to retain a majority stake indicates it views the unit as a strategic asset rather than a non-core divestiture. The company has expanded aggressively into AI across various domains, including large language models and recommendation algorithms. Applying these capabilities to drug discovery represents a natural extension of its research and development efforts.
Read: IIT Madras to launch AI Studio to turn research into startups; opens to outside founders
The spin-off and fundraising come amid heightened global interest in AI applications for healthcare. Pharmaceutical companies are increasingly partnering with AI firms to enhance their pipelines, while regulators grapple with how to evaluate treatments discovered through computational methods.
For Anew Labs, the new capital will likely fund expansion of its research team, computational infrastructure, and drug development programs. The company will need to demonstrate that its AI models can generate leads that translate into successful clinical trials, a challenge that has tripped up several competitors in the past.
While the sources did not disclose specific financial terms beyond the valuation and stake retention, the deal underscores the willingness of investors to fund ambitious AI ventures despite broader economic uncertainty. The participation of state-backed funds also highlights the geopolitical dimension of AI development, where national competitiveness in technology and healthcare increasingly intersect.
The transaction is expected to close in the coming weeks, subject to customary regulatory approvals. Neither ByteDance nor Anew Labs has publicly announced the funding, and representatives for the investors declined to comment when reached by Inside AI.
